Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School recently identified a new method for safe and effective delivery of medicines to the lungs that can be used for multiple clinical applications, potentially including aerosol vaccination.
Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands.
**All experts also available for interviews prior to event and EUA Advisory Committee Meetings** **B-roll and lab photos of Drs. Weissman and Wherry shot this month, headshots of the others, and photos from Penn’s Moderna vaccine trial participants getting vaccinated, are available for use**
A Rutgers philosopher examines the ethical questions around human challenge trials for COVID-19 vaccines
UC Davis Health will launch a COVID-19 clinical trial with Novavax to test a new coronavirus vaccine. This vaccine has an important advantage: liquid state storage that allows for distribution using standard vaccine channels, unlike the Pfizer and Moderna vaccines that must be stored at subzero temperature.
In this free STS webinar, Next Steps in Eradicating COVID-19: Emerging Treatments and Vaccines, STS President Dr. Joseph Dearani will talk with infectious disease experts from the White House Coronavirus Task Force and Mayo Clinic about promising new treatments and preventive measures.
A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.
The American Association of Nurse Anesthetists (AANA) commends the U.S. Centers for Disease Control and Prevention’s (CDC's) team of advisors on prioritizing frontline healthcare personnel and residents of long-term facilities for the first phase of the COVID-19 vaccine distribution.
Chemist Meredith Jackrel studies protein misfolding and how it leads to disease. She is collaborating engineers to develop amyloid-inspired vaccine technologies specifically tailored for seniors. The approach could be relevant to COVID-19 as the elderly are particularly susceptible to its severe complications.
“Following the swi. review— and subsequent guidance— by the NIH and theCDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use willallow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.” —FLCCC Alliance
In a new paper in the journal Nature, BIDMC researchers shed light on the role of antibodies and immune cells in protection against SARS-CoV-2, the virus that causes COVID-19, in rhesus macaques.
Nearly half of all patients served by community health centers (CHCs) qualify for phase one COVID-19 immunizations under priority guidelines established by the Centers for Disease Control and Prevention, according to a new analysis produced by researchers at the Geiger Gibson/RCHN Community Health Foundation Research Collaborative.
As coronavirus cases rage throughout the United States—killing more than a quarter million in the U.S.—news of the effectiveness of vaccine candidates provides hope.
The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis.
Differences in the immune systems and better blood vessel health were among the factors protecting children from severe COVID-19, according to a new review.
Associate Professor Tinglong Dai of the Johns Hopkins Carey Business School, an expert in health care industry operations management and business analytics, examines the daunting process of administering a COVID-19 vaccine globally.
Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.
ADE has not been shown to occur in individuals that received COVID-19 vaccines to date.
More than 90 percent of human papillomavirus (HPV)-related cancers could be prevented by widespread uptake of the HPV vaccine. Yet, vaccine use in the United States falls short of public health goals.
The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths (Figure 1), and a large number of open cases.
Irvine, Calif., Dec. 1, 2020 — The coming of winter means cooler temperatures, shorter days and flu shots. While no one looks forward to a vaccination, a study led by the University of California, Irvine, has found that either a sincere smile or a grimace can reduce the pain of a needle injection by as much as 40 percent. A genuine, or Duchenne, smile – one that elevates the corners of the mouth and creates crow’s feet around the eyes – can also significantly blunt the stressful, needle-related physiological response by lowering the heart rate.
With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.
So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.
Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.
UniSA researchers are evaluating a new vaccination education initiative – the COVID-19 Peer Hub – to help immunisation and public health professionals to tackle the emerging dangers of vaccine hesitancy amid the pandemic.
None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.
B-roll available: Video shot today showing the freezers where Cedars-Sinai will store COVID-19 vaccines. Please note: There are NO vaccines in the video. The vaccines will not arrive until next month.
A new poll of adults ages 50 to 80 suggests that achieving the widespread vaccination against COVID-19 needed to protect this high-risk group and end the pandemic will be an uphill climb, and require clear, transparent communication from health providers and others.
UNLV researcher Edwin Oh and colleagues have implemented wastewater surveillance programs to screen samples for the presence of COVID-19 and to extract the RNA from the SARS-COV-2 virus to find targets that make vaccines more effective.
The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19.
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease.
Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group
A group of vaccine experts led by Children’s Hospital of Philadelphia (CHOP) has published recommendations to ensure equitable distribution of a COVID-19 vaccine when it becomes available. The framework, published today in Heath Affairs, focuses on five principles the authors believe would strengthen the current immunization delivery system to ensure equitable access to everyone for whom vaccination is recommended.
Texas Biomedical Research Institute (Texas Biomed) in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection. MAbs are human-made proteins meant to mimic human immune system antibodies. Texas Biomed Professors Luis Martinez-Sobrido, Ph.D. and Jordi B. Torrelles, Ph.D. will co-lead the project to evaluate the protective efficacy of these MAbs in small rodent models, developed at Texas Biomed, on behalf of the Coronavirus Immunotherapy Consortium (CoVIC), an international nonprofit consortium evaluating MAb therapeutics for COVID-19.
Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.
Anthony S. Fauci, MD, will discuss COVID-19 – including the latest on potential vaccines – in a free Zoom presentation at noon Nov. 18 during Medical Center Hour at the University of Virginia School of Medicine.
Major measles outbreaks will likely occur during 2021 as an unexpected consequence of the COVID-19 pandemic, according to a new academic article.
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right